1stOncology™: Cancer Intelligence Service – Page 9990 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

On June 15, 2021 PTC Therapeutics, Inc. (NASDAQ: PTCT) reported that on June 11, 2021 it approved non-statutory stock options to purchase an aggregate of 118,350 shares of its common stock and 30,835 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 66 new employees(Press release, PTC Therapeutics, JUN 15, 2021, View Source [SID1234584037]). The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires’ employment compensation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The inducement grants were approved by PTC’s Compensation Committee on June 11, 2021 and are being made as an inducement material to each employee’s acceptance of employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).

All stock option awards have an exercise price of $42.95 per share, the closing price of PTC’s common stock on June 11, 2021, the date of the grant. The stock options each have a 10-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s new hire date and 6.25% of the original number of shares vesting at the end of each subsequent three-month period thereafter until fully vested, subject to the employee’s continued service with the Company through the applicable vesting dates. The RSUs each will vest over four years with 25% of the original number of shares vesting on each annual anniversary of the applicable employee’s new hire date until fully vested, subject to the employee’s continued service with the Company through the applicable vesting dates.

Phigenix, Inc. Receives Issuance of U.S. Patent Covering Precision Medicine Diagnostic and Novel Therapeutic for Treating Drug-Resistant Breast Cancer

On June 15, 2021 Phigenix, Inc. Pharmaceutical and Biomedical Research Company, a molecular oncologist-led, biopharmaceutical company focused on identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in diagnosing and precision treatment in oncology, reported that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,033,628, which is directed to methods related to the use and administration of certain PAX2 inhibitors for treating drug-resistant breast cancer(Press release, Phigenix, JUN 15, 2021, View Source [SID1234584036]). Drug resistance of metastatic breast cancers to first-line chemotherapies, either single or a combination of drugs, occurs in 30-70% of cases.

U.S. Patent No. 11,033,628 also covers the use of a diagnostic test that assesses the expression status of PAX2 and Human Beta Defensin-1 (DEFB1) in addition to the current standard of care molecular markers to determine the best course of treatment of breast cancer. Additional issued claims pertain to methods of using anti-PAX2 compositions to treat particular resistant breast cancers. This newly issued patent is owned by Phigenix, Inc and is the latest U.S. patent issued in connection with Phigenix’s PAX2 robust drug and diagnostics development program for cancer detection and treatment.

"We are extremely pleased with the addition of this new patent to our portfolio to extend our cutting-edge, next-generation medical innovations. This new issuance continues to expand the breadth and depth of our PAX2 intellectual property portfolio covering methods of use for certain PAX2 inhibitors and diagnostic tests for effective breast cancer disease treatment and management. The technology covered in this patent has the potential to revolutionize how physicians determine the most effective course of treatment for breast cancer patients. Ultimately, this new technology may make treatment more affordable and save thousands of lives," said Dr. Carlton D. Donald, Founder, President and Chief Executive Officer of Phigenix, Inc.

New Data

On June 15, 2021 Patrys is pleased to report the publication of new data in the highly-regarded Journal of Clinical Investigation – Insight, demonstrating the ability of its PAT-DX1 antibody to cross the blood-brain barrier and inhibit the growth of brain cancers and metastases(Press release, Patrys, JUN 15, 2021, View Source [SID1234584035]).

Most antibodies are unable to cross cell membranes or the blood-brain barrier, limiting their use in treating cancers of the brain. However, this latest research led by Dr James Hansen at Yale School of Medicine has shown the potential of Patrys’ unique deoxymab platform for tackling these difficult-to-reach-and-treat cancers.

Human glioblastoma cells were implanted in the brains of mice, which were then treated with PAT-DX1 once tumours had become established in the brain.

Oncorus to Host Investor Day Featuring its IV-Administered Synthetic Viral RNA (vRNA) Immunotherapy Platform and Lead Synthetic vRNA Product Candidates

On June 15, 2021 Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, reported that it will host an upcoming investor day featuring its intravenous (IV)-administered Synthetic viral RNA (vRNA) Immunotherapy Platform, and its recently nominated lead Synthetic vRNA Immunotherapy product candidates, ONCR-021 and ONCR-788(Filing, 8-K, Oncorus, JUN 15, 2021, View Source [SID1234584034]). The virtual event will take place on June 21, 2021 from 1:00 – 2:30 p.m. ET.

Oncorus Synthetic vRNA Immunotherapies Day Agenda

Leena Ghandi, M.D., Ph.D., Director, Center for Cancer Therapeutic Innovation at the Dana-Farber Cancer Institute, will be a featured speaker at the event. Dr. Ghandi will review current clinical practice and the potential for IV-administered viral immunotherapies to address significant unmet needs.

Oncorus leadership will discuss the company’s pioneering IV-administered approach, which involves encapsulating the genomes of RNA viruses known to kill cancer cells (i.e., oncolytic viruses, or OVs) within a lipid nanoparticle (or LNP), creating a Synthetic vRNA immunotherapy. Oncorus’ novel Synthetic vRNA approach holds the potential for repeat IV administration and avoids the challenge of neutralizing antibodies seen in previous approaches with IV-administered, naturally-occurring OVs.

Oncorus will review preclinical data supporting the ONCR-021 and ONCR-788 candidate nominations and discuss current clinical development plans for each program. ONCR-021 encodes an optimized strain of Coxsackievirus A21 (CVA21), and ONCR-788 encodes a modified version of the Seneca Valley Virus (SVV).

Finally, the company will also provide an overview of its 88,000 square foot state-of-the-art process development and Good Manufacturing Practice (GMP) manufacturing facility in Andover, Mass., which it anticipates will be operational for GMP manufacturing in the first half of 2023.

A live webcast of the event will be available to registered attendees under the Investors and Media section of Oncorus’ website at View Source A replay of the presentation will be archived on Oncorus’ site for 60 days following the event.

For more information or to RSVP, please contact Josh Rauch at [email protected].

Click here to read a white paper published by Oncorus’ leadership on it Synthetic vRNA Immunotherapy Platform and lead candidates.

Lineage Cell Therapeutics to Present at Raymond James 2021 Human Health Innovation Conference on June 22, 2021

On June 15, 2021 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, reported that Brian M. Culley, Chief Executive Officer, will be presenting at the Raymond James 2021 Human Health Innovation Conference being held virtually on June 22, 2021 at 1:20 p.m. Eastern Time / 10:20 a.m. Pacific Time. Interested investors can access the live and archived webcasts on the Events and Presentations section of Lineage’s website(Press release, Lineage Cell Therapeutics, JUN 15, 2021, View Source [SID1234584033]). Additional videos are available on the Media page of the Lineage website.